Forsøg med dendritcellevaccination i kombination med kemoterapi til behandling af patienter med prostatakræft, der har spredt sig

• Conditions: Castration resistent metastatic prostate cancer; MedDRA version: 14.1Level: HLTClassification code 10036908Term: Prostatic neoplasms malignantSystem Organ Class: 100000004864; Therapeutic area: Diseases [C] - Cancer [C04]

• Registration Number: EUCTR2011-001602-10-DK
• Lead Sponsor: Center for Cancer Immunotherapy (CCIT) / Department of Oncology, Herlev Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2011-06-22
• Last Update Posted: 11 April 2016

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: Male
• Target Recruitment: Not specified

Inclusion Criteria

Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 40
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

Not provided

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Main Objective: ;Secondary Objective: ;Primary end point(s): ;Timepoint(s) of evaluation of this end point: End of trial

Secondary Outcome Measures

Name	Time	Method
Secondary end point(s): At beskrive objektivt respons ved hjælp af WHO’s Response Evaluation Criteria in Solid Tumors (RECIST-kriterier).<br><br>At evaluere PSA respons<br><br>At evaluere smerterespons<br><br>At belyse, hvorvidt kombinationsbehandlingen er en tolerabel og sikker behandling <br><br>At beskrive tid til progression samt registrere overlevelsen.<br>;Timepoint(s) of evaluation of this end point: End of trial